Paclitaxel by 3-h infusion and carboplatin in anthracycline-resistant advanced breast cancer. A phase II study conducted by the Hellenic Cooperative Oncology Group (Journal article)

Fountzilas, G./ Athanassiadis, A./ Kalogera-Fountzila, A./ Aravantinos, G./ Bafaloukos, D./ Briasoulis, E./ Dombros, N./ Ioannidis, I./ Pavlidis, N./ Kosmidis, P./ Skarlos, D.

37 patients with advanced breast cancer resistant to anthracyclines were treated with paclitaxel 200 mg/m2 by 3-h infusion and carboplatin at an area under the curve of 7 mg.min/ml every 4 weeks with G-CSF support. There were 5 (14%, 95% CI 3-25%) complete and 11 (30%, 95% CI 15-45%) partial responders. Median duration of response was 11.5 months (range 5.2-16.8+), median time to progression 8 months (range 0.26-16.8+) and median survival 12 months (range 0.5-19.6+). Grade 3-4 leucopenia (27%), thrombocytopenia (10%) and diarrhoea (5%) were noted. In conclusion, the combination of paclitaxel and carboplatin is active and well tolerated in patients with advanced breast cancer resistant to anthracyclines.
Institution and School/Department of submitter: Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής
Keywords: Adolescent,Adult,Aged,Antineoplastic Agents, Phytogenic/administration & dosage,Antineoplastic Combined Chemotherapy Protocols/*therapeutic use,Breast Neoplasms/drug therapy,Carboplatin/administration & dosage,Drug Resistance, Neoplasm,Female,Humans,Infusions, Intravenous,Middle Aged,Paclitaxel/administration & dosage,Treatment Outcome
ISSN: 0959-8049
Appears in Collections:Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά)

Files in This Item:
File Description SizeFormat 
Fountzilas-1997-Paclitaxel by 3-h in.pdf348.26 kBAdobe PDFView/Open    Request a copy

 Please use this identifier to cite or link to this item:
  This item is a favorite for 0 people.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.